Onco Wiki / Biomarcador

Expresión BCL2 por IHC

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDBIO-BCL2-EXPRESSION-IHC
TipoBiomarcador
Aliaces
Linfoma de células B 2BCL2BCL2 expresión por inmunohistoquímicaЕкспресія BCL2 (імуногістохімія)
Situaciónreviewed 2026-04-25 | pending_clinical_signoff
EnfermedadesDIS-AML DIS-CLL DIS-DLBCL-NOS DIS-FL DIS-MCL
FuentesSRC-NCCN-BCELL-2025

Datos sobre biomarcadores

Tipo de biomarcadorprotein_expression_ihc
Medición
MétodoIHC en biopsia de FFPE (anticuerpo anti-BCL2, 124 clones)
Unidadescategorical (positive ≥50% | negative); semi-quantitative percentage often reported
Productos químicos y químicosBIO-BCL2-REARRANGEMENT BIO-DOUBLE-HIT

Notas

Cross-disease relevance: - **CLL/SLL**: BCL2-dependent — venetoclax (BCL-2 inhibitor) is highly active. Universal CLL marker; drives VenO 1L choice for high-risk. - **MCL**: cyclin-D1+ MCL is also BCL2+; predicts venetoclax-rituximab sensitivity in r/r — emerging 2L+ pathway. - **FL**: defining via t(14;18) IGH/BCL2 (~85%) — over-expression blocks apoptosis. Tazemetostat (EZH2 inhibitor) emerging in EZH2-mut r/r FL. - **DLBCL**: double-expressor (BCL2+ ≥50% IHC + MYC+ ≥40% IHC at protein level, distinct from FISH double-hit) is adverse but does NOT change 1L regimen per current evidence. - **HGBL-DH**: BCL2 rearrangement is part of double-hit definition (with MYC + optionally BCL6). - **MM**: t(11;14) MM subset highly venetoclax-sensitive; emerging therapy. Direct algorithm-driving currently: indirectly via BIO-DOUBLE-HIT in HGBL-DH + via venetoclax-eligible flag in CLL high-risk. Future: drive r/r 2L+ venetoclax pathway across all BCL2-dependent diseases.

Utilizado por

Relevancia terapéutica

Biomarcador

Capítulos del Manual

Indicación

Cuestionarios